Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treximet in Triptan-Nonresponsive Migraine Subjects
NCT00382993Phase 3Completed
- Sponsor
- GSK
- Start
- Dec 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sumatriptan and Aprol in migraine (2 arms), sponsored by GSK. Primary endpoint: Sustained Freedom From Migraine Pain Between 2-24 Hours Post-dose. Started Dec 2006; status: completed.
02
Drugs
sumatriptanAprol
03
Conditions
migraine
Beyond the preview
Go deeper on NCT00382993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00382993.